AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05101551
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose (IV) of gemcitabine on Day 1 of each 28 day cycle for 1 cycle.~* Dose Level -2: 600 mg/m2/dose once daily by IV days 1~* Dose Level -1: 600 mg/m2/dose once daily by IV days 1~* Dose Level 1: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 2: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 3: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 4: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 5: 1200 mg/m2/dose once daily by IV days 1
Trial: NCT04784143
Drug: Midomafetamine
RxNorm normalized name: Midomafetamine
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg midomafetamine HCl followed by a supplemental dose of 60 mg
Trial: NCT04802590
Drug: Ibrutinib 560 mg
RxNorm normalized name: ibrutinib 560 MG
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 560mg/d continuously from C1D2 to end C24
Trial: NCT04802590
Drug: Venetoclax 10 MG Oral Tablet [Venclexta]
RxNorm normalized name: venetoclax 10 MG Oral Tablet [Venclexta]
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20mg/d from C2D1 to C2D7
Trial: NCT04802590
Drug: Venetoclax 50 MG Oral Tablet [Venclexta]
RxNorm normalized name: venetoclax 50 MG Oral Tablet [Venclexta]
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50mg/d from C2D8 to C2D14
Trial: NCT04802590
Drug: Venetoclax 100 MG Oral Tablet [Venclexta]
RxNorm normalized name: venetoclax 100 MG Oral Tablet [Venclexta]
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100mg/d from C2D15 to C2D21 200mg/d from C2D22 to C2D28 400mg/d from C3D1 to end C24
Trial: NCT05494619
Drug: Crovalimab
RxNorm normalized name: Crovalimab
DrugBank: Crovalimab (DB16128)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight ≥ 40 kilograms (kg) and \<100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Day 1, followed by crovalimab 340 mg SC injections on Days 2, 8, 15 and 22 in all participants.
Trial: NCT06342609
Drug: Colchicine 0.5 MG
RxNorm normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg per day of Colchicine orally administered
Trial: NCT04810676
Drug: CKD-383
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT06527131
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: medical antibiotics
Trial: NCT00549289
Drug: cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05645887
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human albumin from day 0 to 7 if serum albumin concentrations \<35g/l.
Trial: NCT05568147
Drug: Aspirin tablet
RxNorm normalized name: Aspirin Tablets
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: When patients are randomized into the intervention group, they will receive aspirin at the dosage of 100mg orally once every day.
Trial: NCT05077709
Drug: IO102-IO103 in combination with pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The experimental drug IO102-IO103 is for SC injection and consist of IDO and PD-L1 peptides
Trial: NCT05696678
Drug: Intrathecal Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.
Trial: NCT05696678
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.
Trial: NCT04969120
Drug: Metoclopramide 10mg
RxNorm normalized name: METOCLOPRAMIDE 10MG ORAL DISINTEGRAT TAB
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: this group receive 10mg intravenous metoclopramide slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
Trial: NCT05453968
Drug: Berotralstat
RxNorm normalized name: Berotralstat
DrugBank: Berotralstat (DB15982)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally once daily at a weight-based dose in up to 4 cohorts
Trial: NCT06511648
Drug: Erdafitinib monotherapy
RxNorm normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive treatment with erdafitinib alone (cohort 1)
Trial: NCT06511648
Drug: Cetrelimab and Erdafitinib combination
RxNorm normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive treatment neoadjuvant with erdafitinib plus cetrelimab intravenously (IV).(cohort 2)
Trial: NCT05555329
Drug: Pomalidomide 4 mg every day in cycle 1
RxNorm normalized name: pomalidomide 4 MG
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide 4 mg every day, on days 1-21 in a cycle of 28 days
Trial: NCT05555329
Drug: Pomalidomide 4 mg every other day in cycle 2
RxNorm normalized name: pomalidomide 4 MG
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide 4 mg every other day, on days 1-21 in a cycle of 28 days
Trial: NCT05555329
Drug: Pomalidomide 2 mg every day in cycle 2
RxNorm normalized name: pomalidomide 2 MG
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide 2 mg every day, on days 1-28 in a cycle of 28 days
Trial: NCT05555329
Drug: Pomalidomide 2 mg every day in cycle 3
RxNorm normalized name: pomalidomide 3 MG
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide 2 mg every day, on days 1-28 in a cycle of 28 days
Trial: NCT05555329
Drug: Pomalidomide 4 mg every other day in cycle 3
RxNorm normalized name: pomalidomide 3 MG
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide 4 mg every other day, on days 1-21 in a cycle of 28 days
Trial: NCT06561243
Drug: BTK inhibitor (Ibrutinib or Acalabrutinib)
RxNorm normalized name: BTK inhibitor CC-292
DrugBank: Spebrutinib (DB11764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adult patients with a chronic B-cell malignancy included in this study will be separate into 2 groups according to the BTK inhibitor (ibrutinib and acalabrutinib)
Trial: NCT04118920
Drug: Topical insulin (4 units)
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N=6: 100 U/ml; 4 units of insulin per application; 40 microliters per drop
Trial: NCT04118920
Drug: Topical insulin (20 units)
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N=6: 500 U/ml; 20 units of insulin per application; 40 microliters per drop
Trial: NCT04118920
Drug: Artificial tears
RxNorm normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N=3, 40 microliters per drop
Trial: NCT06642272
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once daily
Trial: NCT06642272
Drug: Dapagliflozin 10 MG
RxNorm normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once daily
Trial: NCT06639672
Drug: Chemotherapy+PD-1 inhibitor+8Gy x 3f
RxNorm normalized name: Pd-1 x ctla-4 dual checkpoint inhibitor xmab20717
DrugBank: Vudalimab (DB18833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy: 8Gy x 3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
Trial: NCT06639672
Drug: Chemotherapy+PD-1 inhibitor+16Gy x 1f
RxNorm normalized name: Pd-1 x ctla-4 dual checkpoint inhibitor xmab20717
DrugBank: Vudalimab (DB18833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy: 16Gy x 1f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
Trial: NCT05888922
Drug: Minoxidil Tablets
RxNorm normalized name: Minoxidil Tablets
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
Trial: NCT05888922
Drug: Minoxidil Topical
RxNorm normalized name: minoxidil topical
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
Trial: NCT04204616
Drug: Nemolizumab
RxNorm normalized name: Nemolizumab
DrugBank: Nemolizumab (DB15252)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab 30 mg will be administered as subcutaneous (SC) injection.
Trial: NCT04878471
Drug: Pudexacianinium chloride
RxNorm normalized name: CHLORIDE
DrugBank: Pudexacianinium (DB19161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT06225544
Drug: Lumasiran
RxNorm normalized name: lumasiran
DrugBank: Lumasiran (DB15935)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
Trial: NCT06225544
Drug: 0.9% Sodium Chloride (placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo, subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
Trial: NCT05830097
Drug: CBP-1019
RxNorm normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Light yellow to yellow loose lumps or powder；50mg/vial; Infusion for 90 minutes (± 10 minutes), once every 2 weeks.
Trial: NCT04812483
Drug: Eltrombopag (Revolade®)
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) indicated in patients with ITP refractory to first-line drugs or lasting more than 6 months. Administration of Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.
Trial: NCT05713838
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1500 mg Durvalumab, IV, day 1 Q4W (max. 15 cycles)
Trial: NCT05713838
Drug: FLOT
RxNorm normalized name: Flotetuzumab
DrugBank: Flotetuzumab (DB15223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate and 2600 mg/m² fluorouracil as 24 h-infusion, 2 cycles
Trial: NCT00000976
Drug: CD4-IgG
RxNorm normalized name: Human IGG
DrugBank: Recombinant human CD4 immunoglobulin G (DB17812)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000976
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05019105
Drug: ALKS 1140
RxNorm normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active oral dose of ALKS 1140
Trial: NCT05202509
Drug: Obicetrapib
RxNorm normalized name: Obicetrapib
DrugBank: Obicetrapib (DB14890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg obicetrapib tablet
Trial: NCT05810792
Drug: Histamine Dihydrochloride (HDC)
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HDC is administrated in combination with IL-2 as peri- and post-operative treatment in patients undergoing surgery. 0.5 mg HDC is administered twice daily by subcutaneous injections 1 to 3 minutes after each IL-2 injection during three 3 week cycles, with 3-week resting periods inbetween. The first treatment cycle is initated 2 weeks prior to surgery, with an additional 2-3 days rest period during the surgical procedure, before the third treatment week is initiated.
Trial: NCT05810792
Drug: Interleukin-2 (IL-2)
RxNorm normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 is administrated in combination with HDC during three 3 week cycles as peri- and post-operative treatment in patients undergoing surgery. IL-2 is administered twice daily as a subcutaneous injection 1 to 3 minutes prior to the administration of histamine dihydrochloride; each dose of IL-2 is 16,400 IU/kg (1µg/kg).
Trial: NCT04890366
Drug: Dimethyl Fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
Trial: NCT05066373
Drug: EDP1815 capsule A
RxNorm normalized name: EDP1815
DrugBank: EDP1815 (DB16486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP1815 capsule A is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
Trial: NCT05066373
Drug: EDP1815 capsule B
RxNorm normalized name: EDP1815
DrugBank: EDP1815 (DB16486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP1815 capsule B is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
Trial: NCT05066373
Drug: EDP1815 tablet
RxNorm normalized name: EDP1815
DrugBank: EDP1815 (DB16486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP1815 tablet is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The tablet is radio-labeled with approximately 4 MBq 99mTc-DTPA
Trial: NCT05613946
Drug: Lumason
RxNorm normalized name: Lumason
DrugBank: Sulfur hexafluoride (DB11104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
Trial: NCT05613946
Drug: Optison
RxNorm normalized name: Optison
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
Trial: NCT05613946
Drug: Definity
RxNorm normalized name: Definity
DrugBank: Perflutren (DB00556)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
Trial: NCT04696575
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04696575
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04696575
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05644301
Drug: Minocyclin
RxNorm normalized name: Minocyclin
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsule, 100 mg, twice daily, for 12 weeks
Trial: NCT05498090
Drug: Fenofibrate 145 mg
RxNorm normalized name: fenofibrate 145 MG
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate 145 mg PO daily for 4 weeks
Trial: NCT04912518
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patient began to inject DEX intravenously as soon as he enrolled. This study started with the maximum maintenance dose allowed by the label (0.7μg/kg/h). With reference to previous studies, we set 3 pump injection gradients within the range of 0.2-0.7μg/kg/h (0.2μg/kg/h, 0.45μg/kg/h, 0.7μg/kg/h), and based on the patient's heart rate , systolic blood pressure and RASS sedation score to adjust.
Trial: NCT06609083
Drug: THC 30mg
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High dose of THC (30 mg)
Trial: NCT06609083
Drug: THC 5mg
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose of THC (5 mg)
Trial: NCT06609083
Drug: THC 0mg
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo dose of THC (0 mg)
Trial: NCT06609083
Drug: Cigarette Full Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Full nicotine cigarette
Trial: NCT06609083
Drug: Cigarette Reduced Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced nicotine cigarette
Trial: NCT06083571
Drug: Prochlorperazine
RxNorm normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunct
Trial: NCT06083571
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunct
Trial: NCT06644326
Drug: 200 mg Itraconazole
RxNorm normalized name: itraconazole 200 MG
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 100mg capsules
Trial: NCT06644326
Drug: 100mg IkT-148009 Dry
RxNorm normalized name: IKT-001Pro
DrugBank: IKT-001Pro (DB17307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg dry tablet formulation
Trial: NCT06644326
Drug: 50mg IkT-148009 Wet
RxNorm normalized name: IKT-001Pro
DrugBank: IKT-001Pro (DB17307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg wet tablet formulation
Trial: NCT04933422
Drug: CM93
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral capsule of CM93 administered once daily
Trial: NCT00010907
Drug: NPI-028
RxNorm normalized name: NPI 32101
DrugBank: NPI 32101 (DB05264)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00728533
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
Trial: NCT05348122
Drug: Dulaglutide,QW
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
Trial: NCT04907084
Drug: Fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate 160mg pill, taken orally
Trial: NCT06606275
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban is a direct oral anticoagulant (DOAC) that inhibits factor Xa, playing a crucial role in preventing blood clot formation. It is commonly prescribed for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) and for treating and preventing venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).
Trial: NCT06606275
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin is a vitamin K antagonist widely used as an anticoagulant to prevent thromboembolic events, particularly in conditions like atrial fibrillation, venous thromboembolism, and in patients with mechanical heart valves. It inhibits the enzyme vitamin K epoxide reductase, thereby reducing the activation of vitamin K-dependent clotting factors (II, VII, IX, X) and regulatory proteins C and S. Due to its narrow therapeutic index, warfarin requires regular monitoring of the International Normalized Ratio (INR) to optimize anticoagulation while minimizing the risk of bleeding. Warfarin's pharmacokinetics and pharmacodynamics can be influenced by genetic polymorphisms, diet, and drug interactions, necessitating individualized dosing strategies.
Trial: NCT06683807
Drug: Hyperbaric bupivacaine 0.5% (2.5 mL) aspirated immediately after opening the bupivacaine ampule
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parturients will receive spinal anesthesia for elective cesarean delivery with injection of 25 μg fentanyl plus 12.5 mg of hyperbaric bupivacaine 0.5% (2.5 mL) immediately after opening the bupivacaine ampule and directly after immediate aspiration with an unfiltered 3 ml syringe